Comprar Halozen (Brand name: Haldol) Online

• 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
• 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
• 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
• 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
• 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
• Haloperidolum
• γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone

Haloperidol circulates in the blood bound predominantly (90-94%) to plasma proteins ^[7].

Acute oral toxicity (LD50): 71 mg/kg in rats ^[MSDS].

Toxicity of haloperidol may be divided into several categories, according the FDA label:

Cardiovascular Effects

The incidence of sudden death, QT-prolongation, and Torsades de Pointes has been reported in patients treated with this drug. Higher than usual doses of any formulation and intravenous (IV) administration of haloperidol have shown to be associated with a higher risk of QT-prolongation and Torsades de Pointes ^[Label].

Caution is advised in treating patients with other cardiac QT-prolonging conditions (including electrolyte imbalance [particularly hypokalemia and hypomagnesemia], drugs which prolong the QT interval, underlying cardiac abnormalities, hypothyroidism, and familial long QT-syndrome). Depot haloperidol is not to be administered by the IV route ^[Label].

Extrapyramidal Symptoms

Extrapyramidal symptoms are comprised of a group of movement disorders which may include dystonia, akathisia, tardive dyskinesia and parkinsonism. Drug-induced extrapyramidal symptoms have been common knowledge for decades, yet the use of these drugs is still common. Despite this, these symptoms may prove to be long-lasting, and therefore, caution is warranted in the prevention of extrapyramidal symptoms ^[13].

Tardive Dyskinesia

This is a consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs and is known as an extrapyramidal symptom ^[Label]. Although the prevalence of the syndrome appears to be high among the elderly, this is a particularly common occurrence in elderly women ^[Label]

The risk of developing tardive dyskinesia and the risk that it may be irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient over time. However, the syndrome can develop, although much less commonly, after brief periods of treatment at lower doses ^[Label].

There are no known treatments for established cases of tardive dyskinesia. The syndrome may remit, partially or completely, if antipsychotic treatment is removed ^[Label].

Antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. However, some patients may require treatment despite the presence of the syndrome ^[Label].

Neuroleptic Malignant Syndrome (NMS)

A potentially fatal condition, sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been demonstrated in association with antipsychotic drugs treatment. Clinical signs and symptoms of NMS are hyperpyrexia, muscle rigidity, alterations in mental status (including catatonia) and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Other signs include elevated creatine phosphokinase (CPK), myoglobinuria (rhabdomyolysis) and acute kidney failure ^[Label].

General

In addition to the above toxicities, number of cases of bronchopneumonia, some fatal, have followed the use of antipsychotic drugs, including haloperidol. One theory suggests that lethargy and decreased sensation of thirst due to central inhibition may lead to dehydration, hemoconcentration and reduced pulmonary ventilation. Therefore, if the above signs and symptoms appear, especially in the elderly, the physician should institute remedial therapy promptly.

Hematologic Effects

Reports have been made of the occurrence of mild, usually transient leukopenia and leukocytosis, minimal decreases in red blood cell counts, anemia, or a tendency toward monocytosis. Agranulocytosis has rarely been reported to have occurred with the use of haloperidol, and then only in association with other medication ^[Label].

Liver Effects

Impaired liver function and/or jaundice may occur.

Dermatologic Reactions

Maculopapular and acne-like skin reactions and isolated cases of photosensitivity and loss of hair.

Endocrine Disorders

Lactation, breast engorgement, mastalgia, menstrual irregularities, gynecomastia, impotence, increased libido, hyperglycemia, hypoglycemia and hyponatremia ^[Label]

Gastrointestinal Effects

Anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea and vomiting ^[Label]

Autonomic Reactions

Dry mouth, blurred vision, urinary retention, diaphoresis and priapism ^[Label]

Respiratory Effects

Laryngospasm, bronchospasm and increased depth of respiration ^[Label]

Special Senses

Cataracts, retinopathy and visual disturbances ^[Label]

For the non-decanoate formulations, the haloperidol half-life is on average 24 hours after oral administration and 21 hours after intramuscular administration ^[17].